Earnings #2
ARIAD PHARMACEUTICALS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
Three Months Ended
March 31,
1997 1996
Revenue:
Research revenue $1,973,333 $2,058,334
Interest income 292,717 347,725
Total revenue 2,266,050 2,406,059
Operating expenses:
Research and development 4,257,141 3,702,205
General and administrative 758,065 682,971
Interest expense 57,475 71,616
Total operating expenses 5,072,681 4,456,792
Net loss $(2,806,631) $(2,050,733)
Net loss per share $(.15) $(.11)
Weighted average number of shares
of common stock outstanding 19,145,577 18,976,539 |
